Calcipotriol (MC 903) is a synthetic vitamin D3 analogue with high affinity for the vitamin D receptor.

HEK293/MRP1 cells:6.0 ± 1.8 μM, GL261 cells:69.65 µM

METHODS: HaCaT cells were treated with Calcipotriol (10⁻9 M, 10⁻⁷ M, and 10⁻⁵ M), and Western Blot was used to detect the expression levels of target proteins.
RESULTS: IFN-γinduced K17 protein expression in HaCaT cells, and Calcipotriol dose-dependently inhibited this expression. 10⁻⁷ M and 10⁻⁵ M Calcipotriol inhibited K17 protein expression by 58.10% and 70.68%, respectively. [1]
METHODS: AsPC-1 cells were treated with 100 nM Calcipotriol, and Western Blot was used to detect the expression levels of target proteins.
RESULTS: LRP6 protein levels were significantly decreased after Calcipotriol treatment. [2]

METHODS: To study the antitumor activity of Diclofenac, Calcipotriol and Difluoromethylornithine, Diclofenac (100 μg/week), Calcipotriol (0.166 μg/week), calcipotriol (0.166 μg/week), The Difluoromethylornithine (463.3 μg/week) mixture was applied to the dorsal surface of mice once a day, five days a week for 17 weeks.
RESULTS: Compared with the placebo group, the Diclofenac plus Calcipotriol group and Diclofenac plus DFMO plus Calcipotriol group showed significantly less weight gain. [3]